SG11201909552VA - Combination therapy for prostate cancer - Google Patents

Combination therapy for prostate cancer

Info

Publication number
SG11201909552VA
SG11201909552VA SG11201909552VA SG11201909552VA SG 11201909552V A SG11201909552V A SG 11201909552VA SG 11201909552V A SG11201909552V A SG 11201909552VA SG 11201909552V A SG11201909552V A SG 11201909552VA
Authority
SG
Singapore
Prior art keywords
international
johnson
effective amount
therapeutically effective
prostate cancer
Prior art date
Application number
Other languages
English (en)
Inventor
Margaret K Yu
Linda Anne Snyder
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=62067858&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201909552V(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of SG11201909552VA publication Critical patent/SG11201909552VA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
SG11201909552V 2017-04-13 2018-04-09 Combination therapy for prostate cancer SG11201909552VA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762485164P 2017-04-13 2017-04-13
PCT/US2018/026661 WO2018191141A1 (en) 2017-04-13 2018-04-09 Combination therapy for prostate cancer

Publications (1)

Publication Number Publication Date
SG11201909552VA true SG11201909552VA (en) 2019-11-28

Family

ID=62067858

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201909552V SG11201909552VA (en) 2017-04-13 2018-04-09 Combination therapy for prostate cancer

Country Status (30)

Country Link
US (2) US20180296574A1 (pt)
EP (3) EP4176878A1 (pt)
JP (3) JP7141408B2 (pt)
KR (1) KR20190134718A (pt)
CN (1) CN110753545A (pt)
AU (2) AU2018251594A1 (pt)
BR (1) BR112019021466A2 (pt)
CA (1) CA3059562A1 (pt)
CL (1) CL2019002871A1 (pt)
CO (1) CO2019011591A2 (pt)
CR (1) CR20190467A (pt)
DK (1) DK3609497T3 (pt)
DO (1) DOP2019000264A (pt)
EA (1) EA201992430A1 (pt)
ES (1) ES2931052T3 (pt)
HR (1) HRP20221327T1 (pt)
HU (1) HUE060460T2 (pt)
JO (1) JOP20190244A1 (pt)
LT (1) LT3609497T (pt)
MA (1) MA48728B1 (pt)
MD (1) MD3609497T2 (pt)
MX (2) MX2019012296A (pt)
NI (1) NI201900105A (pt)
PE (1) PE20200444A1 (pt)
PH (1) PH12019502317A1 (pt)
PL (1) PL3609497T3 (pt)
PT (1) PT3609497T (pt)
RS (1) RS63832B1 (pt)
SG (1) SG11201909552VA (pt)
WO (1) WO2018191141A1 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA45780A (fr) 2016-07-29 2019-06-05 Janssen Pharmaceutica Nv Méthodes de traitement du cancer de la prostate
WO2020139339A1 (en) * 2018-12-27 2020-07-02 Constellation Pharmaceuticals, Inc. Ezh2 and androgen receptor signaling inhibitors as tools for targeting prostate cancer
CN113546037A (zh) * 2020-04-20 2021-10-26 鲁南制药集团股份有限公司 一种醋酸阿比特龙栓剂及其制备方法
JP2023524808A (ja) * 2020-05-08 2023-06-13 ヤンセン ファーマシューティカ エヌ．ベー． アビラテロン酢酸エステル及びニラパリブの組み合わせでの前立腺癌の治療
EP4197541A1 (en) 2021-12-15 2023-06-21 Hunan Huize Biopharma S&T Co., Ltd Abiraterone acetate-containing composition and application thereof
CN114306236B (zh) * 2021-12-15 2022-10-21 湖南慧泽生物医药科技有限公司 用于负载醋酸阿比特龙的自微乳体系及组合物和应用
WO2023194525A1 (en) * 2022-04-07 2023-10-12 Astrazeneca Ab Combination therapy for treating cancer

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080051380A1 (en) * 2006-08-25 2008-02-28 Auerbach Alan H Methods and compositions for treating cancer
EP3804730A1 (en) * 2006-08-25 2021-04-14 Janssen Oncology, Inc. Compositions for treating cancer
GEP20115337B (en) * 2007-01-10 2011-11-25 St Di Ricerche Di Biologia Molecolare P Angeletti Spa Amide substituted indazoles as poly(adp-ribose)polymerase (parp) inhibitors
CN101932572A (zh) 2008-01-08 2010-12-29 默沙东有限公司 2-{4-[(3s)-哌啶-3-基]苯基}-2h-吲唑-7-羧酰胺的药学可接受的盐
WO2012009475A1 (en) * 2010-07-14 2012-01-19 Oregon Health & Science University Methods of treating cancer with inhibition of lysine-specific demethylase 1
WO2014089324A1 (en) * 2012-12-07 2014-06-12 Calitor Sciences, Llc Substituted cyclic compounds and methods of use

Also Published As

Publication number Publication date
PE20200444A1 (es) 2020-02-28
US20220175801A1 (en) 2022-06-09
JP7407880B2 (ja) 2024-01-04
DK3609497T3 (da) 2022-10-31
HUE060460T2 (hu) 2023-03-28
MX2023009569A (es) 2023-08-22
CA3059562A1 (en) 2018-10-18
JP7141408B2 (ja) 2022-09-22
CN110753545A (zh) 2020-02-04
US20180296574A1 (en) 2018-10-18
WO2018191141A1 (en) 2018-10-18
EA201992430A1 (ru) 2020-02-28
JOP20190244A1 (ar) 2019-10-13
PL3609497T3 (pl) 2023-01-23
EP4176878A1 (en) 2023-05-10
AU2024202346A1 (en) 2024-05-02
CL2019002871A1 (es) 2019-12-27
DOP2019000264A (es) 2020-07-15
PT3609497T (pt) 2023-01-23
JP2022141881A (ja) 2022-09-29
CO2019011591A2 (es) 2020-02-28
MA48728A (fr) 2020-04-08
MX2019012296A (es) 2019-11-28
JP2024023344A (ja) 2024-02-21
PH12019502317A1 (en) 2020-07-06
ES2931052T3 (es) 2022-12-23
JP2020516646A (ja) 2020-06-11
EP4176879A1 (en) 2023-05-10
EP3609497A1 (en) 2020-02-19
AU2018251594A1 (en) 2019-10-24
EP3609497B1 (en) 2022-10-12
CR20190467A (es) 2020-03-09
LT3609497T (lt) 2022-12-12
BR112019021466A2 (pt) 2020-05-12
KR20190134718A (ko) 2019-12-04
MA48728B1 (fr) 2022-10-31
MD3609497T2 (ro) 2023-03-31
HRP20221327T1 (hr) 2023-03-17
NI201900105A (es) 2020-03-11
RS63832B1 (sr) 2023-01-31

Similar Documents

Publication Publication Date Title
SG11201909552VA (en) Combination therapy for prostate cancer
SG11201909325RA (en) 2-amino-quinoline derivatives
SG11201806515RA (en) Eribulin-based antibody-drug conjugates and methods of use
SG11201900344YA (en) Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor
SG11201901715UA (en) Adenovirus armed with bispecific t cell engager (bite)
SG11201811564QA (en) Methods of treating ovarian cancer
SG11201901126UA (en) Combination therapy for cancer
SG11201808907PA (en) Inhibitors of activin receptor-like kinase
SG11201810423XA (en) Pd-1 / pd-l1 inhibitors for cancer treatment
SG11201906386XA (en) Combination therapy involving diaryl macrocyclic compounds
SG11201909155VA (en) Ask1 inhibitor compounds and uses thereof
SG11201808125RA (en) Methods for solid tumor treatment
SG11201900745VA (en) Substituted thiazolo-pyridine compounds as malt1 inhibitors
SG11201806251WA (en) Methods for treating er+, her2-, hrg+ breast cancer using combination therapies comprising an anti-erbb3 antibody
SG11201810280YA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201900554YA (en) Spiro-lactam nmda modulators and methods of using same
SG11201811559WA (en) Cancer treatment combinations
SG11201900551WA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201900558RA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201407340YA (en) Treatment of myelosuppression
SG11201900546UA (en) Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof
SG11201909303TA (en) Point of delivery cold slurry generation
SG11201809751XA (en) Egfr inhibitor compounds
SG11201908517XA (en) Pyrimidinyl-pyridyloxy-naphthyl compounds and methods of treating ire1-related diseases and disorders
SG11201901063SA (en) Therapeutic agents for neurodegenerative diseases